Pacira BioSciences has been acquired by Viatris for $36.50 per share in cash, completing a tender offer and merger on November 17. Pacira is now a wholly owned subsidiary of Viatris, and its remaining public shareholders’ shares were converted into the right to receive the same cash price.
The transaction also changed how Pacira’s convertible notes are settled, unwound related capped-call contracts and ended the company’s bank credit agreement.
Key details
-
Tender offer completed: Viatris said 32,929,780 Pacira shares were validly tendered and not withdrawn, representing about 66.46% of shares outstanding. That was enough to meet the offer’s minimum condition, and all other conditions were satisfied or waived. Viatris accepted the tendered shares for payment on November 17.
-
Merger followed the offer: After the tender offer, Viatris merged its acquisition subsidiary into Pacira. Pacira survived as a wholly owned Viatris subsidiary. The merger was completed without a separate Pacira stockholder vote.
-
Cash for remaining shares: Shares outstanding immediately before the merger generally became a right to receive $36.50 in cash per share, without interest and subject to applicable tax withholding. Shares held by Pacira, Viatris and their subsidiaries were excluded, as were shares whose holders properly exercised appraisal rights.
-
Treatment of employee options: Outstanding Pacira stock options, whether vested or unvested, were canceled. Holders of options with an exercise price below $36.50 are entitled to cash equal to the difference between the offer price and the exercise price, multiplied by the number of shares under the option, subject to tax withholding. Options with an exercise price equal to or above $36.50 were canceled without payment.
-
Convertible notes remain outstanding: Pacira had $287.5 million in principal outstanding on its 2.125% convertible senior notes due 2029. After the merger, each $1,000 of principal can be converted only into cash, calculated as $36.50 multiplied by the applicable conversion rate. Payment is due on the 10th business day after conversion. For certain conversions associated with the merger, the calculation also includes any additional shares provided for under the notes’ make-whole provisions.
-
No merger-related repurchase offer for noteholders: Pacira elected not to offer to repurchase the notes in connection with the merger. The notes were not described as having been repaid.
-
Capped-call contracts unwound: Pacira entered into agreements with each capped-call counterparty to unwind contracts originally arranged in connection with the notes. The counterparties agreed to pay Pacira cash on or about November 17; the amount was not specified.
-
Credit facility ended: Pacira repaid the $96,392.50 outstanding under its credit agreement. The agreement and all remaining commitments were terminated, and liens securing obligations under it are to be released.
Plain-English implications
Pacira’s public shareholders have been cashed out at $36.50 per share, and Viatris now controls the company. Pacira’s 2029 convertible notes remain in place, but conversion now leads to a cash payment tied to the acquisition price rather than shares in Pacira. The company also ended its bank borrowing arrangement, while the disclosed repayment was limited to the small amount outstanding under that facility.
